Document is current
Any future updates will be listed below
-
Authors
Hanahan, Douglas https://orcid.org/0000-0002-0883-5251
Michielin, Olivier https://orcid.org/0000-0003-4926-6355
Pittet, Mikael J. https://orcid.org/0000-0002-2060-4691
- License Information
-
More Information
Article History
Accepted: 23 September 2024
First Online: 24 October 2024
Competing interests
: None of the research results reviewed and discussed here reflect bona fide competing interests. In the interest of full disclosure, D.H. currently serves on the scientific advisory boards of Pfizer Oncology, Opna Bio, 4D Molecular Therapeutics and Cellestia, and is a founder of Opna Bio, which has licensed an EPFL patent describing the RNA-binding protein FMRP as a new cancer target. O.M. has served as an adviser for Roche, Novartis, GSK, BMS, MSD, Regeneron, Pierre-Fabre, Merck and Amgen, and is a scientific board member of Cellula Therapeutics. M.J.P. has served as an adviser for AstraZeneca, ImmuneOncia, LegoChem Bio, MaxiVax, Merck, Molecular Partners, Third Rock Ventures, Tidal and Unikum.
